Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $27.50.
A number of analysts have weighed in on the stock. Piper Sandler assumed coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price objective on the stock. Wolfe Research started coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "outperform" rating and a $29.00 price target for the company. Stifel Nicolaus began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued a "buy" rating and a $28.00 price objective for the company. Wells Fargo & Company started coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set an "overweight" rating and a $28.00 target price on the stock. Finally, Bank of America started coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a "buy" rating and a $30.00 target price for the company.
Get Our Latest Research Report on Kestra Medical Technologies
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new position in shares of Kestra Medical Technologies during the first quarter worth about $33,000. Virtu Financial LLC acquired a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $210,000. Armistice Capital LLC purchased a new position in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $312,000. Zimmer Partners LP acquired a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $374,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth approximately $457,000.
Kestra Medical Technologies Price Performance
Kestra Medical Technologies stock traded down $0.11 during midday trading on Tuesday, reaching $22.19. The company's stock had a trading volume of 113,936 shares, compared to its average volume of 198,857. The stock's 50-day moving average is $23.74. Kestra Medical Technologies has a fifty-two week low of $20.00 and a fifty-two week high of $26.15.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Monday, April 14th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period last year, the business earned ($1.18) earnings per share.
Kestra Medical Technologies Company Profile
(
Get Free ReportWe are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Further Reading

Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.